Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v6-EN | Version v2-FR | |
---|---|---|
Language | English | French |
Date Updated | 2019-05-10 | 2019-04-02 |
Drug Identification Number | 02453835 | 02453835 |
Brand name | PRALUENT | PRALUENT |
Common or Proper name | PRALUENT PEN 150MG/ML | PRALUENT PEN 150MG/ML |
Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
Ingredients | ALIROCUMAB | ALIROCUMAB |
Strength(s) | 150MG | 150MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | SUBCUTANEOUS | SUBCUTANEOUS |
Packaging size | 2 pre-filled pens | 2 pre-filled pens |
ATC code | C10AX | C10AX |
ATC description | LIPID MODIFYING AGENTS, PLAIN | LIPID MODIFYING AGENTS, PLAIN |
Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
Anticipated start date | 2019-05-06 | 2019-05-06 |
Actual start date | ||
Estimated end date | 2019-05-13 | 2019-05-13 |
Actual end date | 2019-05-09 | |
Shortage status | Resolved | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | TEMPORARY SHORTAGE OF PRALUENT, 75mg/mL & 150mg/mL (Alirocumab) We recognize the difficulties that this situation may cause for patients and health care providers. We apologize for any inconvenience resulting from this. Please note that both strengths (75 mg/mL and 150mg/mL) are not equivalent. For more information, please contact your healthcare professional. All efforts are being made to resolve the situation and any update will be communicated on the www.drugshortagescanada.ca website. | TEMPORARY SHORTAGE OF PRALUENT, 75mg/mL & 150mg/mL (Alirocumab) We recognize the difficulties that this situation may cause for patients and health care providers. We apologize for any inconvenience resulting from this. Please note that both strengths (75 mg/mL and 150mg/mL) are not equivalent. For more information, please contact your healthcare professional. All efforts are being made to resolve the situation and any update will be communicated on the www.drugshortagescanada.ca website. |
Health Canada comments |